Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Acquired by Bridge City Capital LLC

Bridge City Capital LLC boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 54.8% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 160,739 shares of the company's stock after purchasing an additional 56,930 shares during the quarter. Harmony Biosciences comprises about 1.6% of Bridge City Capital LLC's holdings, making the stock its 17th largest position. Bridge City Capital LLC owned 0.28% of Harmony Biosciences worth $5,335,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Barclays PLC grew its holdings in shares of Harmony Biosciences by 110.9% during the third quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after buying an additional 40,416 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Harmony Biosciences by 9.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock worth $600,000 after acquiring an additional 1,550 shares during the last quarter. KBC Group NV grew its stake in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares during the period. Yousif Capital Management LLC raised its holdings in Harmony Biosciences by 22.4% in the 4th quarter. Yousif Capital Management LLC now owns 14,325 shares of the company's stock valued at $493,000 after acquiring an additional 2,622 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of Harmony Biosciences by 26.3% during the 4th quarter. State of Alaska Department of Revenue now owns 21,716 shares of the company's stock worth $747,000 after purchasing an additional 4,526 shares during the period. Institutional investors and hedge funds own 86.23% of the company's stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Oppenheimer began coverage on Harmony Biosciences in a research note on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price target on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Harmony Biosciences in a research report on Tuesday, February 11th. They set a "buy" rating and a $55.00 price target on the stock. Mizuho upped their target price on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Needham & Company LLC reiterated a "buy" rating and issued a $49.00 target price on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Finally, HC Wainwright reissued a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and an average price target of $53.00.

Harmony Biosciences Trading Up 1.6%

NASDAQ:HRMY opened at $35.60 on Monday. The business has a fifty day moving average of $31.77 and a 200-day moving average of $34.07. The stock has a market cap of $2.04 billion, a price-to-earnings ratio of 16.87, a PEG ratio of 0.47 and a beta of 0.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 1 year low of $26.47 and a 1 year high of $41.61.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. During the same period in the prior year, the company earned $0.67 EPS. Harmony Biosciences's revenue was up 19.5% on a year-over-year basis. Equities analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.